ASCENDIS PHARMA
LIVE

Serial Number

79225147

Owner

Ascendis Pharma A/S

Attorney

Eric T. Fingerhut

Filing Date

Oct 11, 2017

Add to watchlist:

No watchlists yet
View on USPTO

ASCENDIS PHARMA Trademark

Serial Number: 79225147 • Registration: 6630735

ASCENDIS PHARMA is a trademark filed by Ascendis Pharma A/S on October 11, 2017. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 45 (Legal & Security Services). The application is currently registered and active.

Owner Contact Info

Ascendis Pharma A/S (9 trademarks)

Tuborg Boulevard 5
Hellerup 2900 , DK

Entity Type: 16

Trademark Details

Filing Date

October 11, 2017

Registration Date

February 1, 2022

Published for Opposition

November 16, 2021

Goods & Services

Licensing of industrial property; legal services

Scientific research within the medical, pharmaceutical and bacteriological area and providing scientific consultancy and information in relation to the aforementioned scientific research, conducting of tests regarding medical applications, namely, conducting clinical trials for others, packaging design, designing and development of medical equipment, designing pharmaceutical and medical preparations, preparation of pharmaceutical formulations, namely, pharmaceutical products development, design and development of granulation technology and tablet technology and providing scientific consultancy and information relating to the design and development of granulation technology and tablet technology

Pharmaceutical and veterinary preparations for the treatment of physical and mental illness, namely, pharmaceutical preparations for use in enzyme replacement therapy; pharmaceutical and veterinary preparations, namely, vaccines for the treatment of physical and mental illness; pharmaceutical and veterinary preparations for the treatment of physical and mental illness, namely, pharmaceutical preparations for the prevention and treatment of disorders of the endocrine system, growth hormone deficiencies, hypoparathyroidism, achondroplasia, diabetes, fibroblast growth factor receptor(FGFR)-related skeletal disorders, oncological disorders, ophthalmologic disorders, infectious diseases, enzyme replacement therapy, anti-inflammatory diseases, pain, respiratory system disorders, autoimmune disorders, vaccines, non-alcoholic steatohepatitis, brain diseases, bone diseases, CNS diseases, myopathies, obesity, wounds healing, the hormonal system disorders, namely, growth hormone deficiencies, diabetes and angiogenesis, the ophthalmological system disorders, namely, angiogenesis, the angiogenic system disorders, the central nervous system disorders, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, the immune system disorders, namely, immunologic diseases, namely, autoimmune diseases and immunologic deficiency syndromes, the cardio-vascular system diseases, the metabolic system disorders, namely, diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, the respiratory system, the musculo-skeletal system disorders, namely, growth hormone deficiencies, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries, the genitourinary system disorders, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of inflammatory disorders, namely, anti-inflammatories; pharmaceutical preparations for use in dermatology, namely, dermatitis, eczema, psoriasis; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in hematology; pharmaceutical preparations for use in tissue and organ transplantation; pharmaceutical preparations for use in in ophthalmology pharmaceutical preparations for use in the treatment of gastroenterological disorders; sanitary preparations for medical purposes, namely, sanitizing wipes, disinfectants for medical instruments, adhesive tapes for medical purposes, dietetic foods, namely, dietetic sugar substitutes adapted for medical use, all-purpose disinfectants for sanitary purposes; fungicides, herbicides

Filing History

CHANGE OF NAME/ADDRESS REC'D FROM IB
Mar 12, 2026 ADCH
NEW REPRESENTATIVE AT IB RECEIVED
Mar 10, 2024 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Aug 1, 2022 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jul 13, 2022 FICS
FINAL DISPOSITION PROCESSED
Jul 13, 2022 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
May 1, 2022 FICR
REGISTERED-PRINCIPAL REGISTER
Feb 1, 2022 R.PR
NEW REPRESENTATIVE AT IB RECEIVED
Dec 24, 2021 NREP
NOTIFICATION PROCESSED BY IB
Nov 23, 2021 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 16, 2021 NPUB
PUBLISHED FOR OPPOSITION
Nov 16, 2021 PUBO
NEW REPRESENTATIVE AT IB RECEIVED
Oct 28, 2021 NREP
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Oct 27, 2021 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Oct 27, 2021 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 27, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 13, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 12, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 12, 2021 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Oct 12, 2021 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jul 9, 2021 GNFN
FINAL REFUSAL E-MAILED
Jul 9, 2021 GNFR
FINAL REFUSAL WRITTEN
Jul 9, 2021 CNFR
ASSIGNED TO EXAMINER
Jun 10, 2021 DOCK
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 16, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 15, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 15, 2021 TROA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 15, 2021 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 15, 2021 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Mar 15, 2021 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 15, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 15, 2021 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 15, 2021 COAR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 15, 2021 TCCA
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
Mar 15, 2021 EWOR
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Mar 15, 2021 EWAF
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 15, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 15, 2021 REAP
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 14, 2020 GNRN
NON-FINAL ACTION E-MAILED
Sep 14, 2020 GNRT
NON-FINAL ACTION WRITTEN
Sep 14, 2020 CNRT
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Jun 18, 2020 RCCK
ASSIGNED TO LIE
Jun 3, 2020 ALIE
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Nov 21, 2019 RCSC
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jul 5, 2019 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 19, 2019 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jun 19, 2019 OPNR
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
May 9, 2019 RCSC
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Oct 19, 2018 GNS3
LETTER OF SUSPENSION E-MAILED
Oct 19, 2018 GNSL
SUSPENSION LETTER WRITTEN
Oct 19, 2018 CNSL
DATA MODIFICATION COMPLETED
Oct 1, 2018 DMCC
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 28, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 27, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 27, 2018 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 14, 2018 GNRN
NON-FINAL ACTION E-MAILED
Sep 14, 2018 GNRT
NON-FINAL ACTION WRITTEN
Sep 14, 2018 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 17, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 17, 2018 CRFA
ASSIGNED TO LIE
Aug 16, 2018 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 26, 2018 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 24, 2018 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 24, 2018 REAP
REFUSAL PROCESSED BY IB
Mar 2, 2018 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Feb 9, 2018 RFCS
REFUSAL PROCESSED BY MPU
Feb 9, 2018 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 7, 2018 RFCR
NON-FINAL ACTION WRITTEN
Feb 6, 2018 CNRT
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
Feb 2, 2018 RFWR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jan 30, 2018 RFCR
NON-FINAL ACTION WRITTEN
Jan 29, 2018 CNRT
APPLICATION FILING RECEIPT MAILED
Jan 23, 2018 MAFR
ASSIGNED TO EXAMINER
Jan 19, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 19, 2018 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jan 18, 2018 REPR